FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Tactic Pharma LLC
2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2018
3. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [NONE]
(Last)
(First)
(Middle)
C/O SKOKIE BLVD., SUITE 350, 
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

WILMETTE, IL 60091
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common stock 4,111,272.88
I
See Footnotes (1) and (2) (1) (2)
Common stock 166,667
D (1)
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Tactic Pharma LLC
C/O SKOKIE BLVD., SUITE 350
WILMETTE, IL 60091
    X    
Mazar Andrew Paul
1000 SKOKIE BLVD
SUITE 350
WILMETTE, IL 60091
  X   X   Chief Scientific Officer  
Robinson Chandler
C/O SKOKIE BLVD., SUITE 350
WILMETTE, IL 60091
  X   X   Chief Executive Officer  
O'Halloran Thomas V.
C/O MONOPAR THERAPEUTICS INC.
1000 SKOKIE BLVD., SUITE 350
WILMETTE, IL 60091
    X    
Brown Michael J
C/O EURONET WORLDWIDE, INC.
3500 COLLEGE BOULEVARD
LEAWOOD, KS 66211
  X   X    

Signatures

/s/ Kim R. Tsuchimoto, attorney-in-fact 01/08/2018
**Signature of Reporting Person Date

/s/ Kim R. Tsuchimoto, Attorney in fact 01/08/2018
**Signature of Reporting Person Date

/s/Kim R. Tsuchimoto, Attorney in fact 01/08/2018
**Signature of Reporting Person Date

/s/Kim R. Tsuchimoto, Attorney-in-fact 01/08/2018
**Signature of Reporting Person Date

/s/ Kim R. Tsuchimoto, Attorney-In-Fact 01/08/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 3 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein.
(2) Tactic shares voting and investment power over 4,111,272.88 of the shares of common stock held by TacticGem LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.